Becton, Dickinson and Co ( (BDX) ) has released its Q1 earnings. Here is a breakdown of the information Becton, Dickinson and Co presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Becton, Dickinson and Co (BD) is a prominent global medical technology company focused on advancing health care through innovative solutions in medical discovery, diagnostics, and care delivery. BD recently announced its fiscal 2025 first-quarter financial results, showcasing a strong performance with revenue, margins, and earnings surpassing expectations. The company reported a revenue of $5.2 billion, marking a 9.8% increase, and adjusted earnings per share surged by 28% to $3.43. Notably, BD completed a $750 million share repurchase and raised its full-year earnings guidance. Key highlights include BD Medical’s notable growth driven by Medication Delivery Solutions and Management Solutions, while BD Life Sciences saw expansion in Specimen Management and Diagnostic Solutions. Moreover, BD Interventional experienced robust growth in Surgery and Urology & Critical Care. Looking ahead, BD is optimistic about its fiscal year 2025, with adjusted earnings per share expected to grow by around 10% at the midpoint. The company’s strategic plans, including its BD 2025 initiative and the proposed separation of its Biosciences and Diagnostic Solutions units, aim to unlock further growth and innovation.
